Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 101

1.

First-line sunitinib or pazopanib in metastatic renal cell carcinoma: The Canadian experience.

Lalani AA, Li H, Heng DYC, Wood L, Kalirai A, Bjarnason GA, Sim HW, Kollmannsberger CK, Kapoor A, Hotte SJ, Vanhuyse M, Czaykowski P, Reaume MN, Soulieres D, Venner P, North S, Basappa NS.

Can Urol Assoc J. 2017 Mar-Apr;11(3-4):112-117. doi: 10.5489/cuaj.4398.

2.

High fat mass associates with occurrence of targeted therapy-induced left ventricular ejection fraction reduction in patients with renal cell carcinoma.

Kazemi-Bajestani SM, Becher H, Venner P, North S, Baracos V.

Clin Nutr. 2017 Mar 28. pii: S0261-5614(17)30117-6. doi: 10.1016/j.clnu.2017.03.026. [Epub ahead of print]

PMID:
28392165
3.

Avascular Necrosis of the Femoral Head After Palliative Radiotherapy in Metastatic Prostate Cancer: Absence of a Dose Threshold?

Daoud AM, Hudson M, Magnus KG, Huang F, Danielson BL, Venner P, Saluja R, LeGuerrier B, Daly H, Emmenegger U, Fairchild A.

Cureus. 2016 Mar 6;8(3):e521. doi: 10.7759/cureus.521.

4.

Management of advanced kidney cancer: Canadian Kidney Cancer Forum consensus update.

North SA; Canadian Kidney Cancer Forum 2015, Basappa N, Basiuk J, Bjarnason G, Breau R, Canil C, Heng D, Jewett MA, Kapoor A, Kollmannsberger C, Potvin K, Neil Reaume M, Dean Ruether J, Venner P, Wood L.

Can Urol Assoc J. 2015 May-Jun;9(5-6):164-70. doi: 10.5489/cuaj.2894. No abstract available.

5.

A phase I open-labeled, single-arm, dose-escalation, study of dichloroacetate (DCA) in patients with advanced solid tumors.

Chu QS, Sangha R, Spratlin J, Vos LJ, Mackey JR, McEwan AJ, Venner P, Michelakis ED.

Invest New Drugs. 2015 Jun;33(3):603-10. doi: 10.1007/s10637-015-0221-y. Epub 2015 Mar 13.

PMID:
25762000
6.

Enzalutamide in metastatic prostate cancer before chemotherapy.

Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, Iversen P, Bhattacharya S, Carles J, Chowdhury S, Davis ID, de Bono JS, Evans CP, Fizazi K, Joshua AM, Kim CS, Kimura G, Mainwaring P, Mansbach H, Miller K, Noonberg SB, Perabo F, Phung D, Saad F, Scher HI, Taplin ME, Venner PM, Tombal B; PREVAIL Investigators.

N Engl J Med. 2014 Jul 31;371(5):424-33. doi: 10.1056/NEJMoa1405095. Epub 2014 Jun 1.

7.
8.

Management of carcinoma of the penis: Consensus statement from the Canadian Association of Genitourinary Medical Oncologists (CAGMO).

Richter S, Ruether JD, Wood L, Canil C, Moretto P, Venner P, Gingerich J, Emmenegger U, Eisen A, Zalewski P, Joshua A, Mukherjee SD, Heng D, Czaykowski P, Soulieres D, Blais N, Rendon R, Fleshner N, Crook JM, Sridhar SS.

Can Urol Assoc J. 2013 Nov-Dec;7(11-12):E797-811. doi: 10.5489/cuaj.1794. No abstract available.

9.

Genitourinary small-cell carcinoma: a single-institution experience.

Pervez N, El-Gehani F, Joseph K, Dechaphunkul A, Kamal M, Pertschy D, Venner P, Ghosh S, North S.

Curr Oncol. 2013 Oct;20(5):258-64. doi: 10.3747/co.20.1338.

10.

Using the Delphi technique to improve clinical outcomes through the development of quality indicators in renal cell carcinoma.

Wood L, Bjarnason GA, Black PC, Cagiannos I, Heng DY, Kapoor A, Kollmannsberger CK, Mohammadzadeh F, Moore RB, Rendon RA, Soulieres D, Tanguay S, Venner P, Jewett M, Finelli A.

J Oncol Pract. 2013 Sep;9(5):e262-7. doi: 10.1200/JOP.2012.000870. Epub 2013 Jun 4.

PMID:
23943895
11.

Intermittent versus continuous androgen deprivation in prostate cancer.

Hussain M, Tangen CM, Berry DL, Higano CS, Crawford ED, Liu G, Wilding G, Prescott S, Kanaga Sundaram S, Small EJ, Dawson NA, Donnelly BJ, Venner PM, Vaishampayan UN, Schellhammer PF, Quinn DI, Raghavan D, Ely B, Moinpour CM, Vogelzang NJ, Thompson IM Jr.

N Engl J Med. 2013 Apr 4;368(14):1314-25. doi: 10.1056/NEJMoa1212299.

12.

Increased survival with enzalutamide in prostate cancer after chemotherapy.

Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, de Wit R, Mulders P, Chi KN, Shore ND, Armstrong AJ, Flaig TW, Fl├ęchon A, Mainwaring P, Fleming M, Hainsworth JD, Hirmand M, Selby B, Seely L, de Bono JS; AFFIRM Investigators.

N Engl J Med. 2012 Sep 27;367(13):1187-97. Epub 2012 Aug 15.

13.

Management of kidney cancer: canadian kidney cancer forum consensus update 2011.

Jewett M, Finelli A, Kollmannsberger C, Wood L, Legere L, Basiuk J, Canil C, Heng D, Reaume N, Tanguay S, Atkins M, Bjarnason G, Dancey J, Evans M, Fleshner N, Haider M, Kapoor A, Uzzo R, Maskens D, Soulieres D, Yousef G, Basappa N, Bendali N, Black P, Blais N, Cagiannos I, Care M, Chow R, Chung H, Czaykowski P, Derosa D, Durrant K, Ellard S, Farquharson G, Filion-Brulotte C, Gingerich J, Godbout L, Grant R, Hamilton W, Kassouf W, Kurban G, Lane K, Lattouf J, Lau D, Leveridge M, McCarthy J, Moore R, North S, O'brien P, Pituskin E, Racine P, Rendon R, So A, Sridhar S, Stubbs K, Su Z, Taylor L, Udall T, Venner P, Vogel W, Yap S, Yau P, Cooper M, Giroux N, Miron D, Mosher D, Ross K, Willacy J.

Can Urol Assoc J. 2012 Feb;6(1):16-22. doi: 10.5489/cuaj.11273. No abstract available.

14.

Furthering the prostate cancer screening debate (prostate cancer specific mortality and associated risks).

Allan GM, Chetner MP, Donnelly BJ, Hagen NA, Ross D, Ruether JD, Venner P.

Can Urol Assoc J. 2011 Dec;5(6):416-21. doi: 10.5489/cuaj.11063.

15.

Progression-free survival as a clinical trial endpoint in advanced renal cell carcinoma.

Hotte SJ, Bjarnason GA, Heng DY, Jewett MA, Kapoor A, Kollmannsberger C, Maroun J, Mayhew LA, North S, Reaume MN, Ruether JD, Soulieres D, Venner PM, Winquist EW, Wood L, Yong JH, Saad F.

Curr Oncol. 2011 Oct;18 Suppl 2:S11-9.

16.

A phase 2 study of patupilone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel: Canadian Urologic Oncology Group study P07a.

Chi KN, Beardsley E, Eigl BJ, Venner P, Hotte SJ, Winquist E, Ko YJ, Sridhar SS, Weber D, Saad F.

Ann Oncol. 2012 Jan;23(1):53-8. doi: 10.1093/annonc/mdr336. Epub 2011 Jul 16.

PMID:
21765178
17.

International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial.

International Collaboration of Trialists; Medical Research Council Advanced Bladder Cancer Working Party (now the National Cancer Research Institute Bladder Cancer Clinical Studies Group); European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Group; Australian Bladder Cancer Study Group; National Cancer Institute of Canada Clinical Trials Group; Finnbladder; Norwegian Bladder Cancer Study Group; Club Urologico Espanol de Tratamiento Oncologico Group, Griffiths G, Hall R, Sylvester R, Raghavan D, Parmar MK.

J Clin Oncol. 2011 Jun 1;29(16):2171-7. doi: 10.1200/JCO.2010.32.3139. Epub 2011 Apr 18.

18.

Randomized, open-label phase III trial of docetaxel plus high-dose calcitriol versus docetaxel plus prednisone for patients with castration-resistant prostate cancer.

Scher HI, Jia X, Chi K, de Wit R, Berry WR, Albers P, Henick B, Waterhouse D, Ruether DJ, Rosen PJ, Meluch AA, Nordquist LT, Venner PM, Heidenreich A, Chu L, Heller G.

J Clin Oncol. 2011 Jun 1;29(16):2191-8. doi: 10.1200/JCO.2010.32.8815. Epub 2011 Apr 11.

PMID:
21483004
19.

Referral and treatment rates of neoadjuvant chemotherapy in muscle-invasive bladder cancer before and after publication of a clinical practice guideline.

Miles BJ, Fairey AS, Eliasziw M, Estey EP, Venner P, Finch D, Trpkov K, Eigl BJ.

Can Urol Assoc J. 2010 Aug;4(4):263-7.

20.

Canadian consensus guidelines for the management of testicular germ cell cancer.

Wood L, Kollmannsberger C, Jewett M, Chung P, Hotte S, O'Malley M, Sweet J, Anson-Cartwright L, Winquist E, North S, Tyldesley S, Sturgeon J, Gospodarowicz M, Segal R, Cheng T, Venner P, Moore M, Albers P, Huddart R, Nichols C, Warde P.

Can Urol Assoc J. 2010 Apr;4(2):e19-38. No abstract available.

Supplemental Content

Loading ...
Support Center